A Prospective Single Center Trial To Evaluate The Efficacy Of Ledipasvir/ Sofosbuvir (Harvoni)± Ribavirin Versus Ombitasvir/Paritavir/Ritonavir/Dasubuvir (Viekira Pak)± Ribavirin In Treatment-Naive And Experienced Genotype 1 Hepatitis C Virus Infected US Veterans.

Trial Profile

A Prospective Single Center Trial To Evaluate The Efficacy Of Ledipasvir/ Sofosbuvir (Harvoni)± Ribavirin Versus Ombitasvir/Paritavir/Ritonavir/Dasubuvir (Viekira Pak)± Ribavirin In Treatment-Naive And Experienced Genotype 1 Hepatitis C Virus Infected US Veterans.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 May 2016 New trial record
    • 17 Apr 2016 Results (n=132) of SVR12 data until November 2015 were presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top